A phase I/II study of flavopiridol [alvocidib] in relapsed or refractory mantle cell lymphoma (MCL) and diffuse large B-cell lymphoma (DLBCL).

Trial Profile

A phase I/II study of flavopiridol [alvocidib] in relapsed or refractory mantle cell lymphoma (MCL) and diffuse large B-cell lymphoma (DLBCL).

Completed
Phase of Trial: Phase I/II

Latest Information Update: 04 Oct 2012

At a glance

  • Drugs Alvocidib (Primary)
  • Indications Diffuse large B cell lymphoma; Mantle-cell lymphoma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 17 May 2012 Actual end date (1 May 2012) added as reported by ClinicalTrials.gov.
    • 17 May 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 20 Mar 2012 Planned end date changed from 1 Nov 2011 to 1 Apr 2012 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top